TOTAL VOLUME:

$134b

24H VOL:

$107,351,958

24H TRANSACTIONS:

2,388,728,490

OPEN INTEREST:

$1,416,970,024

400,720

Markets across

30,097

events

MATCHED EVENTS:

2,633

PLATFORM COVERAGE:

5

Polymarket:

39%

VS.

Kalshi:

61%

BETA
Dashboards
Insights
Indices
Tour
All
Trending
Breaking
New
Ending Soon
Politics
Sports
Crypto
Companies
Elections
Financials
Economics
Other
Entertainment
Science and Technology
Will Eli Lilly (LLY) Q2 Zepbound sales be above __?
polymarket

Will Eli Lilly (LLY) Q2 Zepbound sales be above __?

Volume:
$4,000

$4.5B

 - Polymarket

$4.5B - Polymarket

1W

News

Positive

Negative

Neutral

Hover marker for details

Vol.

·

Resolved Aug 5, 2026

Closed: Aug 5, 8:48 AM EST

polymarket

Polymarket

View
Outcome
Trade
Chance %
Price
Spread
Liquidity
Volume
24h
7d
Open Interest
Ends in
Result
polymarket

$4.5B

View
100%
Yes 100¢No 0¢
0.1¢
N/A
$2,608
N/A
N/A
N/A
Settled
Yes
polymarket

$4B

View
100%
Yes 100¢No 0¢
0.1¢
N/A
$399
N/A
N/A
N/A
Settled
Yes
polymarket

$5B

View
0%
Yes 0¢No 100¢
—
N/A
$488
N/A
N/A
N/A
Settled
No
polymarket

$6B

View
0%
Yes 0¢No 100¢
—
N/A
$325
N/A
N/A
N/A
Settled
No
polymarket

$5.5B

View
0%
Yes 0¢No 100¢
—
N/A
$180
N/A
N/A
N/A
Settled
No
Total markets: 5

Description

This market will resolve to "Yes" if Eli Lilly's Zepbound total sales for the upcoming second fiscal quarter, as reported in its official company earnings materials, are above the listed amount. Otherwise, this market will resolve to "No". The specified metric will be considered as reported in the company's official earnings materials. Subsequent revisions will not be considered. If the specified company's official earnings materials for the specified quarter are released, and the specified metric is not included, this market will resolve to "No". If the specified company does not release quarterly earnings materials for the specified quarter by September 30, 2026, 11:59 PM ET, this market will resolve to "No". If the specified metric is reported as a range rather than a specific number, the midpoint of the range will be used for resolution of this market. The resolution source for this market is the specified company's official company earnings materials, including press releases, investor presentations, and regulatory filings. If the specified metric is not reported in these materials, recordings or transcripts of the company's earnings webcast may also be used. Note: This market will resolve based on the most numerically precise version of the specified metric reported in the company's official earnings materials. Only the specified metric will be considered; alternate versions that differ in definition or scope from the specified metric will not be considered.

Polymarket

This market will resolve to "Yes" if Eli Lilly's Zepbound total sales for the upcoming second fiscal quarter, as reported in its official company earnings materials, are above the listed amount. Otherwise, this market will resolve to "No". The specified metric will be considered as reported in the company's official earnings materials. Subsequent revisions will not be considered. If the specified company's official earnings materials for the specified quarter are released, and the specified metric is not included, this market will resolve to "No". If the specified company does not release quarterly earnings materials for the specified quarter by September 30, 2026, 11:59 PM ET, this market will resolve to "No". If the specified metric is reported as a range rather than a specific number, the midpoint of the range will be used for resolution of this market. The resolution source for this market is the specified company's official company earnings materials, including press releases, investor presentations, and regulatory filings. If the specified metric is not reported in these materials, recordings or transcripts of the company's earnings webcast may also be used. Note: This market will resolve based on the most numerically precise version of the specified metric reported in the company's official earnings materials. Only the specified metric will be considered; alternate versions that differ in definition or scope from the specified metric will not be considered.

Frequently asked questions

The dashboard tracks real-time odds and price movements for the Eli Lilly Zepbound sales market on Polymarket. It shows how traders value the likelihood of Q2 sales hitting certain thresholds, along with current volume of $4,000 and 24-hour volume of $711. This gives you a live snapshot of market sentiment and trading activity as the event approaches.

On Polymarket, odds reflect the collective bet of traders on Q2 Zepbound sales outcomes. These can diverge from traditional analyst forecasts, which may be more conservative or influenced by different data sets. Where analysts see a cautious outlook, this market might price in higher or lower probabilities based on recent trading patterns and new information flow.

This market resolves around Aug 5, 2026, with the outcome confirmed once the event is verifiable from credible public reporting. The final sales figure for Q2 will be compared against the threshold in the market title, and the result will be settled accordingly based on official company announcements and trusted financial data sources.

Key signals include quarterly earnings releases, FDA updates, changes in demand forecasts, and any major news about Zepbound’s usage or competition. Unexpected shifts in patient enrollment, supply chain issues, or management guidance can also cause rapid moves. Traders will watch these developments closely as they could significantly alter the perceived likelihood of hitting the sales target.